Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma

British Journal of Haematology

Volumn 105, Issue 2, 1999, Pages 412-419

  Wterzbowska, Agnieszka ^a   Urbańska Ryś, Halina ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Interleukin 11; Interleukin 6; Multiple myeloma; Oncostatin M; Soluble interleukin 6 receptor

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032901005     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.1999.01350.x     Document Type: Article

References (45)

1. Bataille, R., Chappard, D. & Klein, B. (1992) Mechanisms of bone lesions in multiple myeloma. Hematology/Oncology Clinics of North America, 6, 285-298.
2. Bataille, R., Jourdan, M., Zhang, X.G. & Klein, B. (1989) Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation, 84, 2008-2011.
3. Castell, J.V., Gomez-Lechon, M.J., David, M., Fabra, R., Trullenque, R. & Heinrich, P.C. (1990) Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology, 12, 1179-1186.
4. Castell, J.V., Gomez-Lechon, M.J., David, M., Mirano, T., Kishimoto, T. & Heinrich, P.C. (1988) Recombinant human interleukin-6 (TL-6)/BSF2/IISF regulates the synthesis of acute phase proteins in human hepatocytes. Federation of European Biochemical Societies Letters, 232, 347-350.
5. Durie, B.G.M. (1986) Staging and kinetics of multiple myeloma. Seminars in Oncology, 13, 300-309.
6. Durie, B.G.M. & Salmon, S.E. (1975) A clinical staging system for myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842-854.
7. Fattori, E., Della Rocca, C., Costa, P., Giorgio, M., Dente, B., Pozzi, L. & Ciliberto, G. (1994) Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood, 83, 2570-2579.
8. Gaillard, J.P., Bataille, R., Brailly, H., Zuber, C., Yasukawa, K., Attal, M., Maruo, N., Taga, T., Kishimoto, T. & Klein, B. (1993) Increased and highly stable levels of functional soluble intrleukin-6 receptor in sera of patients with monoclonal gammopathy. European Journal of Immunology, 23, 820-824.
9. Gu, Z.J., Zhang, X.G., Hallet, M.M., Lu, Z.Y., Wijdenes, J., Rossi, J.F. & Klein, B. (1996) A ciliary neurotrophic factor-sensitive human myeloma cell line. Experimental Hematology, 24, 1195-1200.
10. Hata, H., Matsuzaki, H., Takeya, M., Yoshida, M., Sonoki, T., Nagasaki, A., Kuribayashi, N., Kawano, F. & Takatsuki, K. (1995) Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood, 86, 1939-1945.
11. Hawley, R.G. (1994) Hematopathology of interleukin-6 type cytokines. Stem Cells, 12 (Suppl. 1), 155-171.
12. Hitzler, J.K., Martinez-Valdes, H., Bergsagel, D.B., Minden, M.D. & Messner, H.A. (1991) Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of disease. Blood, 78, 1996-2004.
13. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramato, A. & Kishimoto, T. (1988) Autocrine generation and requirement of BSF-2/IL,-6 for human multiple myeloma. Nature, 332, 83-85.
14. Kishimoto, T., Akira, S., Narazaki, M. & Taga, T. (1995) Interleukin-6 family of cytokines and gp130. Blood, 86, 1243-1254.
15. Kishimoto, T., Akira, S. & Taga, T. (1992) Interleukin-6 and its receptor: a paradigm for cytokines. Science, 258, 593-597.
16. Kishimoto, T., Taga, T. & Akira, S. (1994) Cytokine signal transduction. Cell, 76, 253-256.
17. Kiss, T.L., Lipton, J.H., Bergsagel, D.E., Meharchand, J.M., Jamal, N., Minden, M.D. & Messner, H.A. (1994) Determination of IL6, IL1, and IL4 in the plasma of patients with multiple myeloma. Leukemia and Lymphoma, 14, 335-340.
18. Klein, B. (1995) Cytokine, cytokine receptors, transduction signals and oncogenes in multiple myeloma. Seminars in Hematology, 32, 4-19.
19. Klein, B. & Bataille, R. (1992) Cytokine network in human multiple myeloma. Hematology/Oncology Clinics of North America, 6, 273-284.
20. Klein, B., Harousseau, J.L. & Bataille, R. (1993) Cytokine and cytokine receptors in human multiple myeloma. Hematology/ Oncology Clinics of North America, 6, 273-284.
21. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. & Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73, 517-526.
22. Klein, B., Zhang, X.G., Lu, Z.Y. & Bataille, R. (1995) Interleukin-6 in human multiple myeloma. Blood, 85, 863-872.
23. Koskela, K., Pelliniemi, T.T., Remes, K., Rajamaki, A. & Pulkki, K. (1997) Serum oncostatin M in multiple myeloma: association with prognostic factors. British Journal of Haematology, 96, 158-160.
24. Kyle, R.A. (1994) Independent prognostic value for plasma cell labelling index (PCLI), immunofluorescence microscopy plasma cell percent (IMPCM), beta 2-microglobulin (β2M), soluble interleukin-6 receptor (sIL-6R), and C-reactive protein (CRP) in myeloma trial E9487. (Abstract). Blood, 84, (Suppl. 1), 385a.
25. Kyrtsonis, M.C., Dedoussis, G., Baxevanis, C., Stamatelou, M. & Maniatis, A. (1996a) Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). British Journal of Haematology, 92, 420-422.
26. Kyrtsonis, M.C., Dedoussis, G., Zervas, C., Perifanis, V., Baxevanis, C., Stamatelou, M. & Maniatis, A. (1996b) Soluble interleukin-6 receptor (sIL-6R) a new prognostic factor in multiple myeloma. British Journal of Haematology, 93, 398-400.
27. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R. & Berenson, J. (1995) Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunology, 162, 248-255.
28. Lin, L.F., Mismer, D., Lile, J.D., Armes, L.G., Butler, E.T., Vannice, J.L. & Collins, F. (1989) Purification, cloning, and expression of ciliary neurotrophic factor (CNTF). Science, 246, 1023-1025.
29. Lu, Z.Y., Gu, Z.J., Zhang, X.G., Wijdenes, J., Nedderman, P., Rossi, J.F. & Klein, B. (1995) Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines. Federation of European Biochemical Societies Letters, 377, 515-518.
30. Lu, Z.Y., Zhang, X.G., Gu, Z.J., Yasukawa, K., Amiot, M., Etrillard, M., Bataille, R & Klein, B. (1994) A highly sensitive quantitative bioassay for human interleukin-11. Journal of Immunological Methods, 173, 19-26.
31. Ludwig, H., Nachbaur, D.M., Fritz, E., Krainer, M. & Huber, H. (1991) Interleukin-6 is a prognostic factor in multiple myeloma. Blood, 7, 2794-2795.
32. Nishimoto, N., Ogata, A., Shima, Y., Tani, Y., Ogawa, H., Nakagawa, M., Sugiyama, H., Yoshizali, K. & Kishimoto, T. (1994) Oncostatin M, leukemia inhibitory factor, and interleukin-6 induce the proliferation of human plasmocytoma cells via common signal transducer, gp130. Journal of Experimental Medicine, 179, 1343-1347.
33. Ohtani, K., Ninomiya, H., Hasegawa, Y., Kobayashi, T., Kojima, H., Nagasawa, T. & Abe, T. (1995) Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias. British Journal of Haematology, 91, 116-120.
34. Pulkki, K., Pelliniemi, T.T., Rajamaki, A., Tienhaara, A., Laakso, M. & Lahtinen, R. (1996) Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. British Journal of Haematology, 92, 370-374.
35. Robak, T., Gladalska, A. & Stepien, H. (1998a) The tumor necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. European Cytokine Network, 9, 145-154.
36. Robak, T., Gladalska, A., Stepien, H. & Robak, E. (1998b) Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators of Inflammation, 7, 347-353.
37. Robak, E., Sysa-Jedrzejowska, A., Robak, T., Stepien, H., Wozniacka, A. & Waszczykowska, E. (1996) Tumor necrosis factor α (TNF-α), interleukin-6 and their soluble receptors (sTNF-α-R p55 and sIL-6R) serum levels in systemic lupus erythematosus. Mediators of Inflammation, 5, 435-441.
38. Robak, E., Sysa-Jedrzejowska, A., Stepien. H & Robak, T. (1997) Circulating interleukin-6 types cytokines in patients with systemic lupus erythematosus. European Cytokine Network, 8, 281-286.
39. Stasi, R., Brunetti, M., Parma, A., Di Giulio, C., Terzoli, E. & Pagano, A. (1998) The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer, 82, 1860-1866.
40. Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yakusawa, K., Matsuda, T., Hirano, T. & Kishimoto, T. (1989) Interleukin-6 triggers the association of its receptor with a possible signals transducer, gp130. Cell, 58, 573-581.
41. Taga, T., Narazaki, M., Yusakawa, K., Saito, D., Miki, D., Hamagucki, M., Davis, S., Shoyab, M., Yancopoulos, G.D. & Kishimoto, T. (1992) Functional inhibition of hematopoietic and neurotropic cytokines by blocking the interleukin-6 signal transducer gp130. Proceedings of the National Academy of Sciences of the United States of America, 89, 10998-11001.
42. Thaler, J., Fechner, F., Herold, M. & Huber, H. (1994) Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index. Leukemia and Lymphoma, 12, 265-271.
43. Westendorf, J.J. & Jelinek, D.F. (1996) Growth regulatory pathway in myeloma. Journal of Immunology, 157, 3081-3088.
44. Zhang, X.G., Gu, J.J., Lu, Z.Y., Yasukawa, K., Yancopoulos, G.D., Turner, K., Shoyab, M., Taga, T., Kishimoto, T., Bataille, R., and Klein, B. (1994) Ciliary neurotrophic factor, interleukin-11, leukemia inhibitory factor and oncostatin M, are growth factors for human myeloma cell lines using the interleukin-6 signal transducer gp130. Journal of Experimental Medicine, 177, 1337-1342.
45. Zhang, X.G., Klein, B. & Bataille, R. (1989) IL-6 is a potent myeloma cell growth factor in patients with aggressive multiple myeloma. Blood, 74, 11-13.